Money train has stopped at this station, volume will soon soar, more news will come out and I'm sure Adam F. from thestreet plans to write an article about this very soon. Same thing he did for HGSI shares could go well over $10 Citi Analyst said could go to $20 Look where HGSI is at now roughly $15! The news is out now. Time to triple your money with positive results is coming. An analyst already said "there is no drug out there in this market" Get ready for an explosion! this is the great next HGSI, DNDN.....here we go! "Currently there is no therapy in the United States approved to treat Parkinson's disease psychosis. Physicians may attempt to address this disorder initially by decreasing the dose of the dopamine replacement drugs, which are administered to patients to manage the motoric symptoms of Parkinson's disease. However, this approach is generally not effective in alleviating psychotic symptoms in most patients and is often associated with the significant worsening of motor function in these patients. We believe that pimavanserin has the potential to address a range of central nervous system indications with large unmet medical needs. Together with Biovail, we plan to leverage our Phase III program in Parkinson's disease psychosis to develop and commercialize pimavanserin for multiple neurological and psychiatric indications that are underserved by currently marketed antipsychotics, including psychosis in patients with Alzheimer's disease." Development Status We are currently conducting a number of studies in our Phase III program with pimavanserin for Parkinson's disease psychosis, including two pivotal trials, an open-label safety extension study, and other NDA supporting studies. We have completed a Phase II clinical trial in which pimavanserin demonstrated motoric tolerability and antipsychotic effects in patients with Parkinson's disease, and was safe and well tolerated in the study. In addition, we have reported positive results from a Phase II clinical trial with pimavanserin as a co-therapy in schizophrenia. The results of this trial demonstrated several advantages of co-therapy with pimavanserin and a sub-maximal dose of risperidone, a commonly prescribed antipsychotic drug, including enhanced efficacy, a faster onset of antipsychotic action, and an improved side effect profile. We also have completed a proof-of-concept clinical study in which pimavanserin induced a significant increase in slow wave sleep in older healthy volunteers.
$4.62 (08/10/09)
